0 0.000180342651036934 -0.000360685302073997 -0.000270513976555466 0.000180342651036934 0.00225428313796213 0.00541027953110906 0.00541027953110906
Sign Up Today X
Thanks for submitting the form.
Stockreport

BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy [Seeking Alpha]

BioMarin Pharmaceutical Inc. (BMRN)  More Company Research Source: Seeking Alpha
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
The investment thesis centers on the potential of VOXZOGO and Amicus's two approved therapies to drive future upside. Current share weakness may present a buying opportunity given VOXZOGO's prospects. Recent price action contrasts with the company's underlying long-term growth narrative. maselkoo99/iStock via Getty Images This is my fourth BioMarin ( BMRN ) article following 01/2025's "BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy". In the interim BioMarin has dropped 12%. In this article I evaluate its progress over the This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of BMRN, ASND, TVTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I may b [Read more]
IMPACT SNAPSHOT EVENT TIME: BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BMRN alerts
from News Quantified
BMRN
NEWS
BMRN
Earnings
BMRN
Analyst Actions
BMRN
SEC Filings
Stockreport

BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy [Seeking Alpha]

BioMarin Pharmaceutical Inc.  (BMRN) 
More Company Research Source: Seeking Alpha
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
The investment thesis centers on the potential of VOXZOGO and Amicus's two approved therapies to drive future upside. Current share weakness may present a buying opportunity given VOXZOGO's prospects. Recent price action contrasts with the company's underlying long-term growth narrative. maselkoo99/iStock via Getty Images This is my fourth BioMarin ( BMRN ) article following 01/2025's "BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy". In the interim BioMarin has dropped 12%. In this article I evaluate its progress over the This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of BMRN, ASND, TVTX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I may b [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS